NEW SAFETY INFORMATION
Johnson & Johnson COVID-19 Vaccine
Updated 4/16/21

On April 13, the CDC and the FDA have recommended a pause in the use of the Johnson & Johnson (Janssen) COVID-19 vaccine due to six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine. This pause is in place until the Advisory Committee on Immunization Practices (ACIP) is able to further review these cases and assess their potential significance. FDA will review that analysis as it also investigates these cases.

The CDC has issued a Health Alert intended, in part, to ensure that the healthcare provider community is aware of the potential for these adverse events and can provide proper management due to the unique treatment required with this type of blood clot.

Another ACIP meeting will take place, Wednesday, May 5, 2021 at 11:00 AM ET, and is open to the public. A link to the webcast is available here.

ADDITIONAL RESOURCES:

- Health care providers are asked to report adverse events to the Vaccine Adverse Event Reporting System at https://vaers.hhs.gov/reportevent.html.
- A recording of the joint CDC and FDA media briefing (April 15) about this issue can be found here.
- COCA Call Regarding the J&J/Janssen Vaccine and CVST (April 15): CDC presented the presented the latest evidence on cerebral venous sinus thrombosis (CVST) with thrombocytopenia associated with the administration of the Johnson & Johnson/Janssen COVID-19 vaccine.
- American Society of Hematology FAQ on Vaccine-Induced Immune Thrombotic Thrombocytopenia